Publication Details
Abstract
Macular pigment optical density (MPOD) is a practical measure of lutein accumulation in the human macula. We examined the NVTIA® high-all-trans lutein crystalline material and then placed its analytical profile beside human intervention data on macular pigment and visual performance. Across five process conditions, total lutein was 81.7-82.8%, all-trans lutein 88.8-89.8%, recovery 79.5-80.6%, and cis isomers 10.2-11.2%. Process comparators produced larger changes: removal of MCT-assisted extraction reduced recovery, omission of low-oxygen/light control shifted all-trans lutein from 89.8% to 84.0% and cis isomers from 10.2% to 16.0%, and omission of pre-deoiling caused emulsification during saponification with greater resin-column resistance. Human evidence available through 18 August 2026 included randomized trials and meta-analyses of lutein-containing interventions. MPOD increased in several adult studies and in more recent pediatric and adolescent trials. Contrast sensitivity, glare, photostress recovery, visual acuity, and AMD progression were less uniform across populations and endpoints. The process data identify a chemically consistent starting material; the clinical literature identifies MPOD as a direct tissue-response measure, with visual-performance tests used as separate functional outcomes.